RGTI
Rigetti Computing
-- 15.4400 NVDA
NVIDIA
-- 139.930 TSLA
Tesla
-- 454.130 LAES
SEALSQ Corp
-- 8.760 KULR
KULR Technology
-- 4.8000 
NEWS
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
X4 Pharmaceuticals (XFOR) announced positive results from its completed six-month Phase 2 trial of mavorixafor in Chronic Neutropenia (CN). The study demonstrated that mavorixafor durably increased participants' mean absolute neutrophil counts (ANC) to normal levels. In combination therapy, it enabled substantial G-CSF dosing reductions (52% at Month 3 and 70% at Month 6) while maintaining normal ANC levels. A sub-study showed that neutrophils mobilized by mavorixafor were as functional as those from healthy donors. The drug was generally well tolerated with no drug-related serious adverse events reported.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Justford : So stock will go down.